Q32 Bio Inc (QTTB)

$6.13 -0.17 (-2.70%)
Market Cap 83.91M
Revenue (ttm) 0.00
Net Income (ttm) -47.73M
EPS (ttm) N/A
PE Ratio 4.98
Forward PE N/A
Profit Margin 55.49%
Debt to Equity Ratio 0.23
Volume 219,200
Avg Vol 198,402
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 54%
Beta 0.14
Analysts Strong Sell
Price Target $14.33

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
scoon42
scoon42 Mar. 13 at 6:59 PM
$QTTB mark my words this will be $10 by May 1st
0 · Reply
Stackdoe101
Stackdoe101 Mar. 13 at 2:16 PM
$QTTB +104% 🙃✨
0 · Reply
GoCoogs
GoCoogs Mar. 13 at 2:03 PM
$QTTB The march to $10 continues
0 · Reply
Stackdoe101
Stackdoe101 Mar. 13 at 2:00 PM
$QTTB 🙃✨
0 · Reply
scoon42
scoon42 Mar. 13 at 12:32 PM
$QTTB 💰💰$8 today 💰💰
0 · Reply
HeavyFt
HeavyFt Mar. 12 at 6:08 PM
$CING and $QTTB Loaded more! ready for moon $TSLA $AAPL
0 · Reply
scoon42
scoon42 Mar. 12 at 4:38 PM
$QTTB up 94% the last month, plenty of momentum to continue, adding more shares load up!
0 · Reply
CEMBP_Trader
CEMBP_Trader Mar. 12 at 4:15 PM
$QTTB Bempikibart data mid year. ADX-096/Platform strategic news can do magic any time. 🍀🎉🍀 “Evaluating strategic next steps for ADX-096 and complement inhibitor platform”
0 · Reply
HoHoHoHum
HoHoHoHum Mar. 12 at 3:23 PM
$QTTB defying gravity. Has a lot more up to go obviously.
0 · Reply
mouse333
mouse333 Mar. 11 at 7:59 PM
$QTTB No bad surprises on earnings. $13 analyst target. Tiny float. Shorts starting to cover. Feels like momentum is just getting started.
0 · Reply
Latest News on QTTB
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 6:59 AM EDT - 7 days ago

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 6:59 AM EST - 27 days ago

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio Announces $10.5 Million Registered Direct Offering

Feb 17, 2026, 6:59 AM EST - 4 weeks ago

Q32 Bio Announces $10.5 Million Registered Direct Offering

Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 3 months ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 3 months ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 3 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 4 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 1 year ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

scoon42
scoon42 Mar. 13 at 6:59 PM
$QTTB mark my words this will be $10 by May 1st
0 · Reply
Stackdoe101
Stackdoe101 Mar. 13 at 2:16 PM
$QTTB +104% 🙃✨
0 · Reply
GoCoogs
GoCoogs Mar. 13 at 2:03 PM
$QTTB The march to $10 continues
0 · Reply
Stackdoe101
Stackdoe101 Mar. 13 at 2:00 PM
$QTTB 🙃✨
0 · Reply
scoon42
scoon42 Mar. 13 at 12:32 PM
$QTTB 💰💰$8 today 💰💰
0 · Reply
HeavyFt
HeavyFt Mar. 12 at 6:08 PM
$CING and $QTTB Loaded more! ready for moon $TSLA $AAPL
0 · Reply
scoon42
scoon42 Mar. 12 at 4:38 PM
$QTTB up 94% the last month, plenty of momentum to continue, adding more shares load up!
0 · Reply
CEMBP_Trader
CEMBP_Trader Mar. 12 at 4:15 PM
$QTTB Bempikibart data mid year. ADX-096/Platform strategic news can do magic any time. 🍀🎉🍀 “Evaluating strategic next steps for ADX-096 and complement inhibitor platform”
0 · Reply
HoHoHoHum
HoHoHoHum Mar. 12 at 3:23 PM
$QTTB defying gravity. Has a lot more up to go obviously.
0 · Reply
mouse333
mouse333 Mar. 11 at 7:59 PM
$QTTB No bad surprises on earnings. $13 analyst target. Tiny float. Shorts starting to cover. Feels like momentum is just getting started.
0 · Reply
Nathan202
Nathan202 Mar. 11 at 7:57 PM
$QTTB
0 · Reply
scoon42
scoon42 Mar. 11 at 7:54 PM
$QTTB need it to close over $7.10
0 · Reply
Vouniotis
Vouniotis Mar. 11 at 6:44 PM
$QTTB sold too early at 6.25 today but I can't complain. Bought when it was hammered 1.55. Might get in again if it drops a bit.
4 · Reply
scoon42
scoon42 Mar. 11 at 5:23 PM
$QTTB Spread the word
0 · Reply
scoon42
scoon42 Mar. 11 at 5:18 PM
$QTTB earnings per share estimate was .86 actual per share was $3.65 WOW nice beat this is going to have legs for a while!
0 · Reply
Amcollins711
Amcollins711 Mar. 11 at 5:04 PM
$QTTB Nice lil cuppie
0 · Reply
scoon42
scoon42 Mar. 11 at 5:03 PM
$QTTB 🚀🚀Looking for $7.50 by eod !
0 · Reply
Stackdoe101
Stackdoe101 Mar. 11 at 4:38 PM
$QTTB
0 · Reply
Stef_DL
Stef_DL Mar. 11 at 2:56 PM
$QTTB
0 · Reply
Amcollins711
Amcollins711 Mar. 11 at 2:52 PM
$QTTB Run baby, run
0 · Reply